
Neuro-Oncology
Latest News

Latest Videos

Shorts










Podcasts
CME Content
More News

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.

Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.

A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.

The designation for the investigational brain-penetrant IDH1 inhibitor comes as the pivotal phase 3 SIGMA study evaluates its use in patients with high-risk IDH1-mutant astrocytoma.

A new cross-sectional study found that professional identity partially explains the connection between burnout and missed nursing care among neuro-oncology nurses in China, with psychological capital buffering both pathways.

Updated phase 2 data showed durable responses and sustained disease control with safusidenib after nearly 40 months of follow-up, prompting plans for phase 3 and phase 2 studies in newly diagnosed and post-vorasidenib IDH1-mutant glioma.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

A nonrandomized controlled trial found that an MCT program added to standard rehabilitation significantly improved MoCA scores and reduced anxiety and depression at 4 and 12 weeks compared with standard care alone.

Bevacizumab becomes approved in Japan for neurofibromatosis type 2 following phase 2 data that suggested potential effects on hearing preservation and tumor volume despite the study not meeting its primary efficacy end point.

First-time seizures were associated with more than a 5-fold increase in short-term cancer risk and persistent long-term risk in a nationwide cohort study of nearly 50,000 adults.

Since paraneoplastic neurologic syndromes remain underrecognized in oncology, experts recently discussed diagnostic challenges, treatment strategies, and the need for clinical vigilance.

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

Paraneoplastic Neurologic Syndromes Present Before Testicular Germ Cell Tumor Diagnosis, Study Shows
In a recent study of patients with testicular germ cell tumors, most exhibited paraneoplastic neurologic syndromes proceeding with their cancer diagnosis, often associated with specific neural autoantibodies.

AHN's neuro-oncology program aims to revolutionize brain and spine tumor care with innovative therapies, personalized treatment plans, and advanced research initiatives.

A newly presented study showed that patients with sarcopenia before starting chemotherapy had a greater likelihood of developing moderate to severe peripheral neurotoxicity.

A duo of experts from Weill Cornell Medicine talked about the advancements made in diffuse midline gliomas research and clinical trials that may offer new hope for improving its historically poor prognosis.














